Первый прямой ингибитор ренина алискирен: новые перспективы нефропротекции при сахарном диабете
Первый прямой ингибитор ренина алискирен: новые перспективы нефропротекции при сахарном диабете
Шестакова М.В., Кутырина И.М. Первый прямой ингибитор ренина алискирен: новые перспективы нефропротекции при сахарном диабете. Consilium Medicum. 2009; 11 (12): 61–66.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Шестакова М.В., Кошель Л.В., Вагодин В.А., Дедов И.И. Факторы риска прогрессирования диабетической нефропатии у больных с длительным течением сахарного диабета по данным ретроспективного анализа. Тер. арх. 2006; 6: 24–7.
2. Tuck M.L., Sambhi M.P., Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus. Studies of the autonomic nervous system\'s control of rennin release. Diabetes 1979; 28: 237–41.
3. Bell G.M., Bernstein R.K., Laragh J.H. et al. Increased plasma atrial natriuretic factor and reduced plasma rennin in patients with poorly controlled diabetes mellitus. Clin Sci 1989; 77: 177–82.
4. Bojestig M, Nystrom F, Arnqvist H.J. et al. The renin - angiotensin - aldosteron system is suppressed in adults with type 1 diabetes. JRAAS 2000; 1: 353–6.
5. Campbell D.J. The site of angiotensin production. J Hypertens 1985; 3: 199–207.
6. De Mello W.C. Is an intracellular rennin - angiotensin system involved in control of cell communications in heart? J Cardiovasc Pharmacol 1994; 23: 640–6.
7. Griendling K.K., Ushio-Fukai M, Lassegue B et al. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997; 29: 366–73.
8. Kang J.J., Toma I, Sipos A et al. The collecting duct is the major source of prorenin in diabetes. Hypertension 2008; 51: 1597–604.
9. Schmieder R.E. The potential role of prorenin in diabetic nephropathy. J Hypertens 2007; 27: 1323–6.
10. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом типа 2 и диабетической нефропатией. Тер. арх. 2008; 1: 49–52.
11. Uresin Y, Taylor A.A., Kilo C et al. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosteron Syst 2007; 8: 190–8.
12. Nussberger J, Wuerzner G, Jensen C et al. Angiotensin II suppression in humans by the orally active rennin inhibitor aliskiren (SPP 100): comparison with enalapril. Hypertension 2002; 39: 1–8.
13. Stanton A, Jensen C, Nussberger J et al. Blood pressure lowering in essential hypertension with an oral rennin inhibitor aliskiren. Hypertension 2003; 42: 1137–43.
14. Oparil S, Yarows S.A., Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double - blind trial. Lancet 2007; 370: 221–9.
15. Waldmeier F.J., Glaenzel U, Wirz B et al. Absorption, distribution, metabolism and elemenation of the direct rennin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35: 1418–28.
16. Sanoski C.A., Pharm D. Aliskiren: an oral rennin inhibitor for the treatment of hypertension. Pharmacotherapy 2009; 29: 193–212.
17. Parving H.H., Persson F, Lewis J.B. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
2. Tuck M.L., Sambhi M.P., Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus. Studies of the autonomic nervous system\'s control of rennin release. Diabetes 1979; 28: 237–41.
3. Bell G.M., Bernstein R.K., Laragh J.H. et al. Increased plasma atrial natriuretic factor and reduced plasma rennin in patients with poorly controlled diabetes mellitus. Clin Sci 1989; 77: 177–82.
4. Bojestig M, Nystrom F, Arnqvist H.J. et al. The renin - angiotensin - aldosteron system is suppressed in adults with type 1 diabetes. JRAAS 2000; 1: 353–6.
5. Campbell D.J. The site of angiotensin production. J Hypertens 1985; 3: 199–207.
6. De Mello W.C. Is an intracellular rennin - angiotensin system involved in control of cell communications in heart? J Cardiovasc Pharmacol 1994; 23: 640–6.
7. Griendling K.K., Ushio-Fukai M, Lassegue B et al. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension 1997; 29: 366–73.
8. Kang J.J., Toma I, Sipos A et al. The collecting duct is the major source of prorenin in diabetes. Hypertension 2008; 51: 1597–604.
9. Schmieder R.E. The potential role of prorenin in diabetic nephropathy. J Hypertens 2007; 27: 1323–6.
10. Шамхалова М.Ш., Трубицына Н.П., Шестакова М.В. Феномен частичного ускользания блокады ангиотензина II у больных сахарным диабетом типа 2 и диабетической нефропатией. Тер. арх. 2008; 1: 49–52.
11. Uresin Y, Taylor A.A., Kilo C et al. Efficacy and safety of the direct rennin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosteron Syst 2007; 8: 190–8.
12. Nussberger J, Wuerzner G, Jensen C et al. Angiotensin II suppression in humans by the orally active rennin inhibitor aliskiren (SPP 100): comparison with enalapril. Hypertension 2002; 39: 1–8.
13. Stanton A, Jensen C, Nussberger J et al. Blood pressure lowering in essential hypertension with an oral rennin inhibitor aliskiren. Hypertension 2003; 42: 1137–43.
14. Oparil S, Yarows S.A., Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double - blind trial. Lancet 2007; 370: 221–9.
15. Waldmeier F.J., Glaenzel U, Wirz B et al. Absorption, distribution, metabolism and elemenation of the direct rennin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35: 1418–28.
16. Sanoski C.A., Pharm D. Aliskiren: an oral rennin inhibitor for the treatment of hypertension. Pharmacotherapy 2009; 29: 193–212.
17. Parving H.H., Persson F, Lewis J.B. et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–46.
Авторы
Шестакова М.В., Кутырина И.М.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.